Learn how the new SCAI guidance regarding PCI within non-surgical facilities broadens the use of plaque modification devices in all U.S. cath labs. We’ll dig into intravascular lithotripsy’s (IVL) mechanism of action and how lithotripsy bridges the gap between a safe and effective calcium modification technology for use in facilities lacking on site surgical backup. Our expert panel will share patient cases that benefit from Shockwave IVL, why clinicians need to take a ‘wholistic approach’ and how lithotripsy is positively impacting patient outcomes and key facility metrics from both operational and economic perspectives.
Learn From Our Experts About:
- What physicians and administrators need to know about the new guidance on PCI within facilities without cardiac surgical backup
- What is IVL? What clinical data exists demonstrating safety, efficacy and intuitiveness?
- Why the new guidance recommends IVL a plaque modification option across all U.S. cath labs
- How IVL is being utilized clinically in facilities lacking on site surgical backup
- Why keeping patients close to home is a win-win from a patient and clinical perspective
- How IVL positively impacts key facility metrics by increasing patient volumes within the same patient population
Who should watch:
- Chiefs/Directors of Interventional Cardiology and Cardiology
- Interventional Cardiologists
- Cardiovascular Service Line Directors
- ASC and OBL CEOs, COOs, Administrators and Business Managers
- Hospital and Health System C-Suite - COOs, CEOs, CFOs
Panel:
Moderator: Alexander G. Truesdell, MD, FACC, FSCAI |
Poonam Velagapudi, MD, MS, FACC,FSCAI Structural and Interventional Cardiologist, Assistant Professor of Medicine, University of Nebraska Medical Center; Co-Author of the SCAI Expert Consensus Statement on Percutaneous Coronary Intervention Without On-Site Surgical Backup |
Clay Sizemore, MD, FACC, FSCAI |
Chris Newman, PharmD, MSHA |
